Please assess the completion status of the following clinical trial:

Trial Title: A Study of LY3463251 in Healthy Participants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy males and females~Exclusion Criteria:~* Diagnosed with Type 1 or Type 2 diabetes~* Women who are of childbearing potential or who are breastfeeding~* Donated blood of more than 500 millilitres (mL) within the previous 3 months of study screening~* Have used any tobacco product within 3 months of Day -1, or are unwilling to refrain from the use of tobacco during the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- LY3463251 Single dose (Type: EXPERIMENTAL): Single dose of LY3463251 administered subcutaneously (SC)
- Placebo Single dose (Type: PLACEBO_COMPARATOR): Single dose of placebo administered SC
- LY3463251 Multiple Dose (Type: EXPERIMENTAL): Multiple doses of LY3463251 administered SC
- Placebo Multiple Dose (Type: PLACEBO_COMPARATOR): Multiple doses of placebo administered SC

Based on this trial design, predict the completion outcome and termination type (if applicable).